Gender-Dependent Growth and Insulin-Like Growth Factor-1 Responses to Growth Hormone Therapy in Prepubertal Growth Hormone-Deficient Children

Witkowska–Sędek, Ewelina; Rumińska, Małgorzata; Majcher, Anna; Pyrżak, Beata

doi:10.1007/5584_2018_284

Cited by 3 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The trends were different from the Phase III clinical trial of Jintrolong ® , in which IGF-1 SDS reached a plateau at around week 13 and then gradually decreased with the same dose of 0.2 mg/kg/week ( Luo et al, 2017 ). This difference may be attributed to the huge inter-individual variation in IGF-1 levels which are influenced by sex, age, body weight, nutritional status, and puberty stage and so on ( Liu et al, 2019 ; Witkowska-Sędek et al, 2019 ; Papathanasiou et al, 2021 ). The previously mentioned cohort study reported that IGF-1 SDS in the PEG-rhGH group reached the upper limit of the normal range (0.96 ± 1.39) during the first 6 months and continued to increase over the next 18 months ( Qiao et al, 2019 ).…”

Section: Discussionmentioning

confidence: 99%

Short-term efficacy and safety of a lower dose of polyethylene glycol recombinant human growth hormone in children with growth hormone deficiency: A randomized, dose-comparison study

et al. 2022

View full text Add to dashboard Cite

Objective: Polyethylene glycol recombinant human growth hormone (PEG-rhGH, Jintrolong®) is the first long-acting rhGH preparation that is approved to treat children with growth hormone deficiency (GHD) in China. Clinical experience with dose selections of PEG-rhGH is scarce. The present study compared the efficacy and safety of a lower dose to increase dosing regimens of PEG-rhGH treatment.Methods: A multicenter, randomized, open-label, dose-comparison clinical study was conducted to compare the improvements in the height standard deviation score (Ht SDS), height velocity (HV), insulin-like growth factor-1 (IGF-1) SDS, and safety profiles of children with GHD who are treated with 0.2 mg/kg/week of PEG-rhGH dose or 0.14 mg/kg/week for 26 weeks.Results: Ht SDS, HV, and IGF-1 SDS increased significantly after PEG-rhGH treatment in the two dose groups (p < 0.05). The improvements of Ht SDS, HV, and IGF-1 SDS were more significant in the high-dose group than in the low-dose group (p < 0.05). Ht SDS improvement in low-dose group was not non-inferiority to that in the high-dose group (p = 0.2987). The incidences of adverse events were comparable between the two groups.Conclusion: The improvements of Ht SDS, HV, and IGF-1 SDS were more significant in the high-dose group than in the low-dose group (p < 0.05). PEG-rhGH at the dose of 0.14 mg/kg/week was effective and safe for children with GHD.Clinical Trial Registration:clinicaltrials.gov, identifier NCT02908958.

show abstract

Section: Discussionmentioning

confidence: 99%

Short-term efficacy and safety of a lower dose of polyethylene glycol recombinant human growth hormone in children with growth hormone deficiency: A randomized, dose-comparison study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…On the basis of previous reference for prophylactic treatment, guessing preventive treatment could be sensitized and relieved the disease as soon as possible to alleviate unnecessary pain. As our understanding deepens, its clinical adaptation gradually expand from the initial prevention and treatment of children's short stature to chronic kidney disease and to be used in burn wound treatment . On the basis of published data, we hypothesized that rhGH could alleviate IR flap damage via inhibiting inflammation and apoptosis.…”

Section: Introductionmentioning

confidence: 99%

Recombinant human growth hormone treatment of mice suppresses inflammation and apoptosis caused by skin flap ischemia–reperfusion injury

Liu

Wang

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Background This study was to investigate the effects of recombinant human growth hormone (rhGh) on ischemia‐reperfusion (I/R) injury of mouse flaps. Methods Healthy mice were randomly divided into four groups as follows: sham group, the IR group, the sham+rhGH group and the IR+rhGH group, with 12 mice in each group. Skin pathology was tested by hematoxylin and eosin staining. The flap survival of each group was measured after 7 days. The levels of superoxide dismutase (SOD) and malondialdehyde (MDA) were determined using corresponding kit. The levels of interleukin (IL)‐6 and tumor necrosis factor (TNF)‐α in serum and flap were respectively measured by performing enzyme‐linked immunosorbent assay and quantitative real‐time (qRT)‐PCR. The expressions of cleaved caspase‐3, B cell lymphoma/leukemia‐2 (Bcl‐2), Bcl‐2‐associated X protein (Bax), vascular endothelial growth factor (VEGF), MnSOD, toll‐like receptor 4 (TLR4), and galectin‐3 and (p)‐p65 were analyzed by RT‐PCR or/and Western blot. Results Prophylactic systemic application of recombinant human GH reduced the pathological damage of skin IR and significantly improved the flap survival of IR in mice, accompanied by elevation of VEGF. After administration of recombinant human GH, the activity of SOD/MnSOD in the flap was significantly increased, while the content of MDA was decreased. Cleaved caspase‐3 and Bax were downregulated and Bcl‐2 was upregulated in IR+rhGH group, compared to IR group. The levels of TLR4, Galectin‐3 and p‐p65 were decreased by rhGH. Conclusion rhGH had protective effects on flap IR injury, and can be used as a drug intervention target for the treatment of skin flap IR injury.

show abstract

Levels and diagnostic values of serum visceral adipose tissue-derived serine protease inhibitor and secreted frizzle-related protein 5 in children with idiopathic short stature

Che

Chen

Hou

et al. 2023

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

Background: Idiopathic short stature (ISS) is a common type of short stature. We aimed to analyze the diagnostic values of serum visceral adipose tissue-derived serine protease inhibitor (Vaspin) and secreted frizzle-related protein 5 (SFRP5) for ISS children. Methods: Sixty-five ISS children treated from February 2019 to June 2022 were selected as an ISS group, while another 65 healthy children receiving physical examination in the same period were selected as a healthy group. Their general data, physical development status, levels of serum Vaspin and SFRP5, and levels of serum growth hormone-releasing hormone (GHRH)/growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis-related indicators were compared. Results: The ISS group had lower body height, body weight, bone age, growth velocity and serum SFRP5 level and higher serum Vaspin level than those of the healthy group (P<0.05). The levels of serum GHRH, GH and IGF-1 were lower in the ISS group than those in the healthy group (P<0.05). Body height, body weight, bone age, growth velocity, and levels of GHRH, GH and IGF-1 were negatively correlated with serum Vaspin level (r<0, P<0.05) but positively correlated with serum SFRP5 level (r>0, P<0.05). The areas under the ROC curves of serum Vaspin and SFRP5 and their combination for the diagnosis of ISS were 0.871 [95% confidence interval (CI): 0.812-0.929], 0.880 (95% CI: 0.824-0.935) and 0.942 (95% CI: 0.907-0.977), respectively. Conclusions: Children with ISS have a higher level of serum Vaspin but a lower level of SFRP5, and the combined detection has a higher diagnostic value for ISS.

show abstract

Gender-Dependent Growth and Insulin-Like Growth Factor-1 Responses to Growth Hormone Therapy in Prepubertal Growth Hormone-Deficient Children

Cited by 3 publications

References 35 publications

Short-term efficacy and safety of a lower dose of polyethylene glycol recombinant human growth hormone in children with growth hormone deficiency: A randomized, dose-comparison study

Short-term efficacy and safety of a lower dose of polyethylene glycol recombinant human growth hormone in children with growth hormone deficiency: A randomized, dose-comparison study

Recombinant human growth hormone treatment of mice suppresses inflammation and apoptosis caused by skin flap ischemia–reperfusion injury

Levels and diagnostic values of serum visceral adipose tissue-derived serine protease inhibitor and secreted frizzle-related protein 5 in children with idiopathic short stature

Contact Info

Product

Resources

About